NCT05811416View on ClinicalTrials.gov

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

September 26, 2025

Study Completion Date

September 26, 2025

Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Trial Locations (1)

08008

Local Institution - 0001, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05811416 - A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants | Biotech Hunter | Biotech Hunter